Product Approval
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
A1 A2 A3 A4 A5
MRNA
FY2026 Q1
Улучшается
Отчётный звонок Moderna, Inc.
Вывод Buzzberg
First flu-COVID combo vaccine approved in EU, fourth product approved.
Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery.
Вывод Buzzberg First flu-COVID combo vaccine approved in EU, fourth product approved. Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery. Читать полный анализСвернуть анализ
Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery.
- EU approval of the first flu+COVID combination vaccine (mCombriax) and MnexPak approvals in the EU are key regulatory wins, positioning for 2027 launches.
- Completed a $950M settlement with Arbutus/Genebon; a potential $1.3B further liability is not reserved.
- Initiated a new Phase III lung cancer study in stage 1 disease, potentially expanding INT to a wider patient population.
Выручка$0.389B-43% к/к
EPS$-3.40Факт
Свободный денежный поток$-0.692BФакт
Капзатраты$0.062BФакт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Pipeline
New Phase 3 trial in stage one NSCLC initiated.
Demand
UK spring and fall deliveries expected; international revenue strong.
Показать ещё 3 тезиса
Pipeline
Norovirus Phase 3 fully enrolled, data expected in 2026.
Pipeline
PA program pivotal data expected later this year; MMA deferred.
Costs
R&D costs down 24% YoY, adjusted cash costs down 26%.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $0.389B | -43% к/к |
| EPS | $-3.40 | Факт |
| Свободный денежный поток | $-0.692B | Факт |
| Капзатраты | $0.062B | Факт |
| Чистая прибыль | $-1.343B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Капзатраты | FY2026 | $0.2B–$0.3B | $0.25B | Подтверждён |
| Выручка | FY2026 | $0B | $0B | Подтверждён |
| Выручка | FY2026 | $4.5B–$5B | $4.75B | Обозначен |
| Выручка | FY2026 Q2 | $0.05B–$0.1B | $0.075B | Обозначен |
| Выручка | FY2026 Q1 | $0.4B | $0.4B | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in execution, highlighting strong Q1 performance, reiterating guidance, and emphasizing multiple upcoming catalysts across the pipeline.
Оценка AI от менеджмента
Management highlighted ongoing investment in AI with cross-enterprise projects to reinvent work and drive personal productivity, positioning AI as a tool to accelerate discovery and expand mRNA into new modalities.
все упомянутые компании ниже: 4
Компаниис момента звонка
Партнёры
Партнёры
Stephen Hogue
The initiation of the INT Phase III in stage 1 lung cancer as a monotherapy is a significant expansion of the addressable market and a potentially pivotal trial. — Success could open a huge market segment where treatment is surgery and watchful waiting, and also support a monotherapy profile for INT.
Доказательства
“We and our partner, Merck, have been really excited by the clinical data that we've seen within TIS4N to date”
Партнёры
Stéphane Boncel
CEPI's support is funding Moderna's pandemic flu program, now in Phase III, a non-commercial partnership.
Доказательства
“we support from CEPI, our pandemic flu program, mRNA-1018, has now initiated its phase three study”
Цепочка поставок
Цепочка поставок
Jamie Mock
A settlement payment shared with Arbutus will be a cash inflow for Geneosoma, but the exact split is not disclosed.
Доказательства
“we entered into a settlement agreement with Arbutus and Genobon, resolving all litigation with them worldwide.”
Внешние сигналы
Альфа цепочки поставок · 5с момента звонка
The initial flu+COVID combo vaccine (mCombriax) approval in the EU creates manufacturing complexity for Moderna, but they expect no revenue in 2026, indicating launch is back-end loaded to 2027.
Доказательства
“we do not expect revenues in the year of approval for these vaccines. And so, 1083 or M-combriax or flu in the United States, none of those are in our guidance”
A $950M settlement payment to Arbutus/Genebon is due in Q3 2026, but Moderna has not reserved the potential $1.3B Section 1498 liability, creating a binary cash risk event in 2027-2028.
Доказательства
“If, however, the Federal Circuit affirms liability under Section 1498, Moderna has agreed to make an additional payment of up to $1.3 billion.”
mRNA-1010 flu vaccine receives PDUFA date of August 5, 2026 in the US; FDA review is progressing 'normal course' with no commentary on new CBER leadership affecting the review.
Доказательства
“we are awaiting further guidance from the FDA on the next steps for resuming filing in the United States.”
The initiation of the INT Phase III in stage 1 lung cancer as a monotherapy is a significant expansion of the addressable market and a potentially pivotal trial.
Доказательства
“the right approach there was to go into a phase three, potentially pivotal study.”
The MMA program has been deferred until after PA readout, indicating management is prioritizing the more de-risked PA program for capital allocation.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 4. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.